Abstract
Heredopathia atactica polyneuritiformis, or simply Refsum disease, is an extremely rare autosomal recessive disorder of phytanic acid accumulation in plasma and various tissues. It typically occurs in the Scandinavian and Northern European countries. Patients with Refsum disease suffer from deficient activity in phytanoyl-CoA hydroxylase, a peroxisomal enzyme that phytanic acid, reaches cytotoxic levels. The disease is characterized by the tetrad of retinitis pigmentosa, polyneuropathy, cerebellar ataxia and elevated CSF protein. Variability in the clinical features includes ichthyosis, anosmia, cardiac arrhythmia, hearing loss and epiphyseal dysplasia.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Quinlan CD, Martin EA. Refsum’s syndrome: report of 3 cases. J Neurol Psychiat. 1970;33:817–23.
Refsum S. Heredoataxia hemeralopica polyneuritiformis - et tidligere ikke beskrevet familiært syndrom? En foreløbig meddelelse. Nordisk Medicin,1945;28:2682–6.
Refsum S. Heredopathia atactica polyneuritiformis. Acta Psychiat 1946 (Kbh.); Suppl: 38.
Jansen GA, Hogenhout EM, Ferdinandusse S, et al. Human phytanoyl-CoA hydroxylase: resolution of the gene structure and the molecular basis of Refsum’s disease. Hum Mol Genet. 2000;9(1):195–200.
Jansen GA, Ferdinandusse S, Hogenhout EM, et al. Phytanoyl-CoA hydroxylase deficiency. Enzymological and molecular basis of classical Refsum disease. Adv Exp Med Biol. 1999;466:371–6.
Jansen GA, Ofman R, Ferdinandusse S, et al. Refsum disease is caused by mutations in the phytanoyl-CoA hydroxylase gene. Nat Genet. 1997;17:190–3.
Singh I, Pahan K, Singh AK, Barbosa E. Refsum disease: a defect in the alpha-oxidation of phytanic acid in peroxisomes. J Lipid Res. 1993;34:1755–64.
Jansen GA, Waterham HR, Wanders RJA. Molecular basis of Refsum disease: sequence variations in Phytanoyl-CoA hydroxylase (PHYH) and the PTS2 receptor (PEX7). Hum Mutat. 2004;23:209–18.
Wierzbicki AS, Mitchell J, Lambert-Hammill M, et al. Identification of genetic heterogeneity in Refsum’s disease. Eur J Hum Genet. 2000;8:649–51.
Claridge KG, Gibberd FB, Sdey MC. Refsum disease: the presentation and ophthalmic aspects of Refsum disease in a series of 23 patients. Eye. 1002;6:371–5.
Kahlert S, Schonfeld P, Reiser G. The Refsum disease marker phytanic acid, a branched chain fatty acid, affects Ca2+ homeostasis and mitochondria, and reduces cell viability in rat hippocampal astrocytes. Neurobiol Dis. 2005;18:110–8.
Ferdinandusse S, Zomer AW, Komen JC, et al. Ataxia with loss of Purkinje cells in a mouse model for Refsum disease. Proc Natl Acad Sci. 2006;105(17):712–7.
Leys D, Petit H, Bonte-Adnet C, et al. Refsum’s disease revealed by cardiac disorders. Lancet. 1989;1:621.
Davies MG, Marks R, Dykes PJ, Reynolds D. Epidermal abnormalities in Refsum’s disease. Br J Dermatol. 1977;97:401–6.
Traupe H. The ichthyoses: a guide to clinical diagnosis, genetic, counselling and therapy. Berlin: Springer; 1989.
Weinstein R. Phytanic acid storage disease (Refsum’s disease): clinical characteristics, pathophysiology and the role of therapeutic apheresis in its management. J Clin Apheresis. 1999;14:181–4.
Bader PI, Dougherty S, Cangany N, et al. Infantile Refsum disease in four Amish sibs. Am J Med Genet. 2000;90:110–4.
Harari D, Gibberd FB, Dick JP, Sidey MC. Plasma exchange in the treatment of Refsum’s disease (heredopathia atactica polyneuritiformis). J Neurol Neurosurg Psychiatry. 1991;54:614–7.
Gutsche HU, Siegmund JB, Hoppmann I. Lipapheresis: an immunoglobulin-sparing treatment for Refsum's disease. Acta Neurol Scand. 1996;94:190–3.
Pakzad-Vaezi KL, Maberley DA. Infantile Refsum disease in a young adult: case presentation and brief review. Retin Cases Brief Rep. 2014;8:56–9.
Straube R, Gackler D, Thiele A, et al. Membrane differential filtration is safe and effective for the long-term treatment of Refsum syndrome-an update of treatment modalities and pathophysiological cognition. Transfusion Apheresis Sci. 2003;29:85–91.
Tsang SH, Sharma T. Inborn errors of metabolism: Refsum disease. Adv Exp Med Biol. 2018;1085:191–2.
Stähr K, Kuechler A, Gencik M, et al. Cochlear implantation in siblings with Refsum’s disease. Ann Otol Rhinol Laryngol. 2017;126:611–4.
Nogueira C, Meehan T, O'Donoghue G. Refsum’s disease and cochlear implantation. Ann Otol Rhinol Laryngol. 2014;123:425–7.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Panteliadis, C.P., Hagel, C. (2022). Refsum Disease (Heredopathia Atactica Polyneuritiformis). In: Panteliadis, C.P., Benjamin, R., Hagel, C. (eds) Neurocutaneous Disorders. Springer, Cham. https://doi.org/10.1007/978-3-030-87893-1_44
Download citation
DOI: https://doi.org/10.1007/978-3-030-87893-1_44
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-87892-4
Online ISBN: 978-3-030-87893-1
eBook Packages: MedicineMedicine (R0)